Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
botensilimab
- Development stage
- Phase 3
- Lead developer
- Agenus
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Botensilimab is an investigational Fc-engineered IgG1 anti-CTLA-4 human monoclonal antibody developed by Agenus for the treatment of various advanced cancers. It is designed to enhance the body’s immune response against cancer cells by targeting and blocking CTLA-4 (cytotoxic T-lymphocyte-associated protein 4), a protein that acts as a "brake" on the immune system. By inhibiting CTLA-4, botensilimab helps to "release the brakes," allowing T cells to more effectively recognize and attack cancer cells. The Fc engineering is intended to improve efficacy and potentially reduce toxicity compared to earlier-generation anti-CTLA-4 antibodies[3][5].
- Other names
- Fc-enhanced CTLA-4 antibodyAnti-CTLA-4 Monoclonal Antibody AGEN1181Anti-CTLA4 Monoclonal Antibody AGEN1181Anti-CTLA 4 Monoclonal Antibody AGEN1181
02
Targets
FcγRIIIa (Low affinity immunoglobulin gamma Fc region receptor III-A)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)
Beyond the preview
Go deeper on botensilimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on botensilimab.